February 18, 2015 | IceCure Medical, a novel Israeli company whose minimally invasive technology treats tumors, announced that it raised NIS 21.2 million (approx. $5.5 million) from Epoch Partner Investments. IceCure applies cyroblation methods, or conditions of extreme cold, to small malignant and benign tumors. The IceSense3 has achieved US Food & Drug Administration and CE approval for its methods. IceCure Medical was founded in 2006 by Didier Toubia and is headed by CEO Hezi Himelfarb.